Immunoglobulin News and Research RSS Feed - Immunoglobulin News and Research

Research reveals why older adults who undergo general anesthesia experience postoperative delirium

Research reveals why older adults who undergo general anesthesia experience postoperative delirium

Newly published research from the Department of Geriatrics and Gerontology at the Rowan University School of Osteopathic Medicine explains why up to half of older adults who undergo general anesthesia develop postoperative delirium - the sudden onset of confusion, aggression or agitated behavior that could progress to dementia. The findings indicate that older patients who are undergoing surgery may benefit from a less-potent, slower-acting anesthetic. [More]
AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge." [More]
Scientists reveal how non-allergenic pollen mediators can increase allergic reactions

Scientists reveal how non-allergenic pollen mediators can increase allergic reactions

Scientists at Helmholtz Zentrum München and TU München discovered a new mechanism how non-allergenic pollen mediators can enhance allergic reactions. Especially the so-called B cells play a critical role in this process. The results were recently published in the Journal 'Allergy' and might lead to new approaches for therapies. [More]
Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Chronic inflammatory demyelinating polyneuropathy commonly misdiagnosed

Half of patients referred to a specialist centre with a diagnosis of chronic inflammatory demyelinating polyneuropathy do not actually have the condition, report researchers. [More]
Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

New diagnostic criteria were introduced this week for neuromyelitis optica, now called neuromyelitis optica spectrum disorder, which is an inflammatory disease of the central nervous system that is sometimes mistaken for multiple sclerosis. [More]
Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. [More]
Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
UC Santa Barbara professor develops novel therapeutic strategy for PKD

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon. [More]
Autoantibodies play major role in IPF patients with acute exacerbations

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease. [More]
Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

Green Cross Biotherapeutics starts construction on new biopharmaceutical facility in Montreal

This is with great pride that Green Cross Biotherapeutics Inc. kicked off construction today on its biopharmaceutical facility that will be located on the Montreal Technoparc's Saint-Laurent Campus. The CA$315 million project represents one of the largest green field investment projects in Canada in the biopharmaceutical industry, giving place to the construction of the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada. [More]
Pre-POINT trial raises hope for Type 1 diabetes prevention

Pre-POINT trial raises hope for Type 1 diabetes prevention

Giving oral insulin to children at genetic high risk of diabetes stimulates a regulatory immune response without inducing hypoglycaemia, show the findings of the Pre-POINT study. [More]
French clinicians diagnose first case of rabies since 2003

French clinicians diagnose first case of rabies since 2003

A team of French clinicians has diagnosed the first case of rabies in that country since 2003. Only 20 cases of human rabies had been diagnosed in France between 1970 and 2003. Moreover, the patient was unaware of having been bitten. [More]
NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines. [More]
Newly approved drug for rare blood cancer shows sustained benefit for 2 years

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute. [More]
Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%. [More]
CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

Since December, there have been more than 130 confirmed cases of measles in the state of California, most of them connected to an outbreak that originated in a Southern California amusement park. Many of the infected persons were not vaccinated against the extremely contagious virus, which manifests itself through rash, fever and coughing. [More]
Newly discovered bodily process may explain fetal brain bleeds

Newly discovered bodily process may explain fetal brain bleeds

A newly discovered bodily process in mice may explain why some human fetuses who have different antigens than their mothers suffer life-threatening brain bleeds, according to a new study. [More]
Study highlights the treatable causes of cerebellar ataxias

Study highlights the treatable causes of cerebellar ataxias

No cures are possible for most patients who suffer debilitating movement disorders called cerebellar ataxias. But in a few of these disorders, patients can be effectively treated with regimens such as prescription drugs, high doses of vitamin E and gluten-free diets, according to a study in the journal Movement Disorders. [More]
Advertisement
Advertisement